The 24 analysts offering 12-month price forecasts for Regeneron Pharmaceuticals Inc have a median target of 622.00, with a high estimate of 734.00 and a low estimate of 400.00. The median estimate represents a -2.74% decrease from the last price of 639.53.
The current consensus among 27 polled investment analysts is to Buy stock in Regeneron Pharmaceuticals Inc. This rating has held steady since June, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share $5.88
Reporting Date Jul 30
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.